EGFR and non-small cell lung carcinoma: Inhibition of TWIST1 activity using an inhibitor inerlotinib- and osimertinib-resistant NSCLC cells increases their sensitivity tothe cytotoxic effect of EGFR inhibitors in a dose-dependent manner.